Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular President and Director David B. Roberts reported exercising stock options and acquiring common shares of the company. On February 5, 2026, he exercised options for 2,672 shares at
Following these transactions, Roberts directly owned 24,930 shares of common stock. The option grants exercised were fully vested and exercisable, and after the transactions one option grant was fully used while another left 14,054 options outstanding.
LeMaitre Vascular’s Senior Vice President of Operations, Trent G. Kamke, reported exercising stock options and acquiring common shares. On January 8, 2026, he exercised options covering 1,229 shares of common stock at $37.29 per share and 1,115 shares at $48.60 per share. These transactions increased his directly held common stock to 5,646 shares after the first exercise and 6,761 shares after the second.
Following these exercises, he continued to hold stock options directly. After the first transaction, he held 3,690 stock options with a $37.29 exercise price, originally granted on December 2, 2020 and expiring on December 2, 2027. After the second, he held 5,085 stock options with a $48.60 exercise price, granted on December 11, 2021 and expiring on December 11, 2028. Footnotes state these options are fully vested and exercisable.
Conestoga Capital Advisors, a Delaware-based investment adviser, filed an amended Schedule 13G reporting a passive ownership stake in LeMaitre Vascular Inc. common stock as of 12/31/2025. Conestoga reports beneficial ownership of 1,527,429 shares, representing 6.73% of the outstanding common stock. It has sole voting power over 1,424,988 shares and sole dispositive power over 1,527,429 shares, with no shared voting or dispositive power. Conestoga certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LeMaitre Vascular.
LeMaitre Vascular Inc. reported insider activity by its chairman and CEO, who is also a director, involving multiple transactions in company common stock on 12/11/2025 and 12/12/2025. The activity included exercises of stock options at exercise prices of $37.29, $48.6, $47.19 and $54.65, as well as releases of dividend equivalent rights that resulted in share acquisitions at $0 per share.
The filing notes that several dispositions reflect shares withheld by the issuer to cover tax obligations tied to vesting restricted stock units and performance stock units, treated as exempt sales under Rule 16b-3(e). It also records a transfer of 12,100 shares from the reporting person’s direct holdings to the LeMaitre Irrevocable Life Insurance Trust of 2025. After these transactions, the reporting person directly owns 1,682,304 common shares, and 33,400 shares are held indirectly by the trust.
LeMaitre Vascular, Inc. reported insider equity transactions by its president and director dated 12/11/2025 and 12/12/2025. The reporting person acquired small amounts of common stock at $0 per share through the release of dividend equivalent rights tied to earlier restricted and performance stock unit awards. On those same dates, the issuer withheld 297 and 302 shares on multiple transactions to cover tax withholding obligations triggered by the vesting of awards granted on 12/11/2021 and 12/12/2022. After all reported activity, the insider directly owned 22,251 shares of LeMaitre Vascular common stock.
LeMaitre Vascular Inc disclosed insider equity transactions by its Senior V. P., Operations in December 2025. The officer acquired small amounts of common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025, with each right economically equivalent to one share of common stock.
On those dates, the issuer also withheld 90 shares on three separate occasions to satisfy tax withholding obligations tied to the vesting of restricted stock units and performance stock units originally granted in 2021 and 2022. After these transactions, the officer beneficially owned 4,417 shares of common stock directly.
LeMaitre Vascular, Inc. director filed a report of routine equity-related transactions. On 12/11/2025 and 12/12/2025, the director acquired 25, 18, and 18 shares of common stock at a price of $0 per share following the release of dividend equivalent rights tied to prior stock awards. After these transactions, the director directly beneficially owned 10,183 shares of common stock.
The filing shows dividend equivalent rights converting into common stock on a one-for-one basis, connected to restricted stock unit and performance stock unit awards granted in 2021 and 2022. Fractional shares from these rights, if any, were settled in cash, leaving derivative right balances such as 19.974 and 19.291 units outstanding.
LeMaitre Vascular, Inc. disclosed that a director acquired common stock through the vesting of equity-based awards on 12/12/2025. Two transactions converted derivative awards into common stock, each for 5 shares of common stock at a price of $0 per share under transaction code "M," which typically reflects the exercise or conversion of derivative securities.
The new shares came from the release of dividend equivalent rights that were tied to restricted stock unit and performance stock unit awards originally granted on 12/12/2022. Each dividend equivalent right was the economic equivalent of one share of LeMaitre Vascular common stock, and any fractional shares were settled in cash, leaving no remaining dividend equivalent rights outstanding after these vesting events.
A LeMaitre Vascular director reported automatic share acquisitions tied to existing equity awards. On 12/12/2025, dividend equivalent rights linked to stock awards converted into common shares at an exercise price of $0, with the transactions coded as exercises (code M). The director received 5 shares from dividend equivalent rights associated with a restricted stock unit award granted on 12/12/2022 and another 5 shares from rights linked to a performance stock unit award granted on the same date. Fractional shares from these rights, if any, were settled in cash, leaving a remaining balance of 0 dividend equivalent rights.
A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025. The director acquired 5 shares of common stock in each of two transactions at a price of $0 per share, reflecting the release of dividend equivalent rights on a one-for-one basis into common stock.
Following these transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock directly. The derivative positions shown were dividend equivalent rights linked to restricted stock unit and performance stock unit awards granted on 12/12/2022, each right being the economic equivalent of one share. After vesting, the number of these derivative rights was reduced to zero, with any fractional shares settled in cash.
FAQ
What is the current stock price of Lemaitre Vasculr (LMAT)?
What is the market cap of Lemaitre Vasculr (LMAT)?
